SCHEDULE: Venrock Discloses 5.2% Stake in Achieve Life Sciences

Venrock Healthcare Capital Partners and affiliates have reported a 5.2% beneficial ownership stake in Achieve Life Sciences, Inc. following a recent private placement.

Summary

• Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, and Venrock Healthcare Capital Partners EG, L.P. have collectively disclosed a 5.2% beneficial ownership in Achieve Life Sciences, Inc.
• The reporting group holds a total of 5,502,064 shares of common stock, which includes shares issuable upon the exercise of warrants.
• The filing confirms the group's status as passive investors, certifying that the securities were not acquired for the purpose of changing or influencing control of the issuer.
• The ownership percentage is based on a total of 105,409,089 shares, accounting for outstanding shares as of March 24, 2026, and shares issued in an April 17, 2026, private placement.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive development; while it confirms institutional interest, it is a standard regulatory disclosure following a capital raise rather than a fundamental change in company operations.

Positives

• Institutional backing from a specialized healthcare investment firm like Venrock often signals confidence in the issuer's clinical pipeline or strategic direction.
• The investment follows a recent private placement, suggesting the company has successfully secured capital to fund its operations.

Negatives

• The disclosure highlights significant dilution potential due to the inclusion of warrants in the beneficial ownership calculation.
• The reliance on private placements to maintain capital levels can be a concern for long-term retail shareholders regarding equity dilution.

Risks

• The investment is subject to the inherent risks of the biotechnology sector, including clinical trial outcomes and regulatory approval processes.
• The reporting persons hold warrants that, if exercised, increase the total share count, potentially impacting earnings per share for existing holders.

Future Outlook

The reporting persons have indicated they are passive investors and do not currently intend to influence the control of the issuer, though they maintain the right to participate in future corporate actions as shareholders.

Industry Context

StockSavvy.ai notes that institutional filings of this nature in the biotech sector are common following capital raises, as specialized funds often participate in private placements to maintain or increase their positions in promising clinical-stage companies.

Comparison to Industry Standards

• The 5.2% stake is consistent with typical 'block' positions taken by venture-backed healthcare funds in small-cap biotech firms.
• The use of a Schedule 13G (rather than 13D) confirms the standard passive investment strategy employed by firms like Venrock in this asset class.

Stakeholder Impact

• Shareholders may view the entry of a major healthcare-focused investment firm as a validation of the company's clinical prospects.
• Existing shareholders should be aware of the potential dilution from the warrants held by the reporting group.

Next Steps

• The reporting persons will continue to monitor their investment in Achieve Life Sciences.
• Future filings may be required if there are material changes to the percentage of ownership held by the group.

Key Dates

Keywords

Achieve Life Sciences, Venrock, Schedule 13G, Biotech Investment, Institutional Ownership, Private Placement